Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 701–800 of 3,116
Østergaard, S., Jessen, C., Paulsson, J. F., Kasimova, M. A., Conde‐Frieboes, K. W., Straarup, E. M., Skyggebjerg, R. B., Ynddal, L., Sanfridson, A., Wulff, B. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6392 · Cited by 16
Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus
Mszar, R., Katz, M. E., Grandhi, G. R., Osei, A. D., Gallo, A., & Blaha, M. J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01202-w · Cited by 17
Semaglutide versus other GLP-1 receptor agonists in patients with MASLD
Kuo, C.-C., Li, C., Chuang, M., Huang, P., Kuo, H., & Lai, C. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000747 · Cited by 15
SELECTing Treatments for Cardiovascular Disease — Obesity in the Spotlight
Khera, A., & Powell‐Wiley, T. M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2312646 · Cited by 14
Fors, A., Forslund, T., Sundström, A., & Wettermark, B. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03823-9 · Cited by 19
Central nervous system pathways targeted by amylin in the regulation of food intake
Hankir, M. K., & Foll, C. L. (2024) · Biochimie · doi:10.1016/j.biochi.2024.10.012 · Cited by 14
Alammari, N. A., ALSHEHRI, A. S., Khalaf, A. A., Alamri, R., Alhalal, N., Sultan, M. A. A., Ogran, N., Aljohani, R., Alasmari, S. M. S., Alsharif, S. B., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16476 · Cited by 13
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Zeng, Q., Gong, Y., Jiao, W., Xu, J., Chen, X., Xu, R., Liu, Y., Liang, X., Li, G., Liu, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv8734 · Cited by 15
Blackwell, K., Blackwell, M., & Blackwell, T. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01935-1 · Cited by 13
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Hakariya, H., Ohnishi, M., & Tanimoto, T. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15638 · Cited by 12
An, H., Xie, K., & Gan, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1448394 · Cited by 14
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Peripheral Artery Disease in the Legs
McDermott, M. M. (2026) · New England Journal of Medicine · doi:10.1056/nejmcp2501200 · Cited by 18
Wegovy: FDA approves weight loss drug to cut cardiovascular risk
Tanne, J. H. (2024) · BMJ · doi:10.1136/bmj.q642 · Cited by 12
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 23
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 17
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“…CVD but no diabetes, revealed that once-weekly subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% com - pared with placebo over a mean follow-up of 39.8 months, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke [48 ].”
InfluentialGLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“GLP-1RAs reduce HbA1c by 0.8%–1.5% points in people living with T2D and 0.3% points in people with obesity without T2D, depending on baseline levels (48, 49, 59, 69–71).”
InfluentialWaqas, S. A., Ali, D., Afridi, M. K., Siddiqui, H. F., Nazir, A., Greene, S. J., & Khan, M. S. (2025) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2025.105981 · Cited by 11
Ravikulan, R., Chavali, S., Gunton, J. E., & Pasquale, C. G. D. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70085 · Cited by 15
Pazzagli, L., & Lagerros, Y. T. (2024) · Obesity Facts · doi:10.1159/000542682 · Cited by 54
GLP ‐1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity
Bucci, T., Alam, U., Fauchier, G., Lochon, L., Bisson, A., Ducluzeau, P., Lip, G. Y. H., & Fauchier, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16238 · Cited by 11
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Meyhöfer, S. M., Cariou, B., Cercato, C., Colhoun, H. M., Deanfield, J. E., Long, M. T., Jeppesen, O. K., Lincoff, A. M., Lingvay, I., Plutzky, J., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04281-1 · Cited by 13
“…the beneficial effects on ALT, AST and GGT levels occurred early after initiation of semaglutide, a similar pattern seen with glycemia 34 , but that maximal weight loss did not occur until beyond 52 weeks 12 , suggesting the impact on liver enzymes was mediated by more than just weight loss.”
InfluentialSelf-citationAnti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Tartaglia, E., Bucci, T., Rossi, M., Rigutini, A. G., Askarinejad, A., Alam, U., Nabrdalik, K., Boriani, G., & Lip, G. Y. H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02986-0 · Cited by 22
Sequeira, V., Theisen, J., Ermer, K. J., Oertel, M., Xu, A., Weissman, D., Ecker, K., Dudek, J., Faßnacht, M., Nickel, A. G., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15152 · Cited by 14
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Obesity and diabetes in heart disease in women
Fatade, Y. A., Dave, E. K., Vatsa, N., Crumbs, T., Calhoun, A. E., Sharma, A., SHUFELT, C. L., & Mehta, P. K. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.30 · Cited by 14
Diabetic Kidney Disease — Semaglutide Flows into the Mainstream
Herrington, W. G., & Haynes, R. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406408 · Cited by 11
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights
Sarkar, A., Fanous, K., Marei, I., Ding, H., Ladjimi, M. M., MacDonald, R. S., Hollenberg, M. D., Anderson, T. J., Hill, M. A., & Triggle, C. R. (2024) · Vascular Health and Risk Management · doi:10.2147/vhrm.s391808 · Cited by 11
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I., Brown, K., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02147-9 · Cited by 11
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Self-citationPathophysiology of Atrial Fibrillation and Approach to Therapy in Subjects Less than 60 Years Old
Curcio, A., Scalise, R., & Indolfi, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020758 · Cited by 13
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
“Semaglutide, for example, is currently the only FDA-approved peptide drug that offers additional cardiovascular benefits, with a mechanism of action that appears to be independent of weight loss [225,226].”
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
Antza, C., Grassi, G. M., Weber, T., Persu, A., Jordan, J., Nilsson, P. M., Redón, J., Stabouli, S., Kreutz, R. H., & Kotsis, V. (2024) · Blood Pressure · doi:10.1080/08037051.2024.2317256 · Cited by 12
Testosterone Therapy in Older Men: Present and Future Considerations
Yeap, B. B., Tran, C., Douglass, C. M., & McNeil, J. J. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01209-1 · Cited by 11
Temporelli, P. L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae011 · Cited by 13
Katamine, M., Minami, Y., & Ako, J. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22044 · Cited by 19
Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
Turkistani, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1535134 · Cited by 10
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Michaelsen, M. K., Drasbek, K. R., Valentin, J. B., Svart, M. V., Larsen, J. B., Kruuse, C. R., Simonsen, C. Z., & Blauenfeldt, R. A. (2025) · Stroke · doi:10.1161/strokeaha.125.053075 · Cited by 15
Point-Counterpoint Debate: Surgery vs Medical Treatment for the Management of Obesity
Schauer, P. R., & Rothberg, A. E. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae888 · Cited by 16
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“…cardiometabolic comorbidities, where semaglutide is the best-studied compound and has been reported to lower major adverse cardiovascular events 13,278 , improve symptoms and physical function in heart failure with preserved ejection fraction 15,276 , and reduce the risk of worsening heart…”
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
Cardiovascular Prevention: Current Gaps and Future Directions
Dores, H., Santos, J. F., Gil, V. M., & Gonçalves, P. D. A. (2025) · Diagnostics · doi:10.3390/diagnostics16010016 · Cited by 19
“The mechanisms appear to extend beyond weight loss, suggesting direct protective effects on cardiac tissue and metabolic processes [39,40].”
Weight Recidivism After Bariatric Surgery: A Narrative Review
Cao, Q., Kazi, H., Merchant, A. M., & Jawed, A. E. (2025) · The American Surgeon · doi:10.1177/00031348251337161 · Cited by 14
Gupta, N., Babyak, A., Chorbajian, A., Tardio, V., Ballreich, J. M., & Dasgupta, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16627 · Cited by 11
Righetti, R., Cinque, F., Volpe, M. T., & Sebastiani, G. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2385487 · Cited by 13
Hansen, M. K., Mortensen, M. B., Olesen, K. K. W., Thrane, P. G., Thomsen, R. W., & Mæng, M. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae119 · Cited by 12
Weiskirchen, R., & Lonardo, A. (2025) · Medical Sciences · doi:10.3390/medsci13040265 · Cited by 22
“The SELECT trial [35] highlighted that semaglutide administered sc at a dose of 2.4 mg OW was effective in significantly reducing MACE by 20% and slowing the progression of CKD among non-diabetic overweight or obese individuals with preexisting CV. Additionally, semaglutide improved the…”
InfluentialNew and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Crisafulli, S., Alkabbani, W., Paik, J. M., Bykov, K., Tavakkoli, A., Glynn, R. J., Htoo, P. T., Yu, E. W.-Y., Trifirò, G., Wexler, D. J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-01724 · Cited by 16
Lee, H. Y., Ko, S.-H., Park, S., Kim, K., Kim, S.-Y., Cho, I.-J., Cho, E. J., Kim, H. C., Park, J.-H., Ryu, S. K., et al. (2024) · Clinical Hypertension · doi:10.1186/s40885-024-00279-4 · Cited by 10
“Very recently, semaglutide reduced the risk of major cardiovascular events by 20% compared with placebo in non-diabetic patients who are overweight or obese and with pre-existing CVD [75].”
BackgroundLópez-Jiménez, F. A., Cesare, M. D., Powis, J., Shrikhande, S. S., Adeoye, M., Codato, E., Zhou, B., Bixby, H., Evans, N. R., Lara-Breitinger, K. M., et al. (2025) · Global Heart · doi:10.5334/gh.1451 · Cited by 19
Heart–liver co-management in MASLD: from concept to clinical practice
Zhou, X., & Zheng, M. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01144-x · Cited by 14
“…of type 2 diabetes and demonstrated a 26% reduction in cardiovascular events (HR 0.74; 95% CI 0.58–0.95; P < 0.001), and the SELECT trial, which enrolled 17,604 individuals with obesity without diabetes, showing a 20% reduction in cardiovascular events (HR 0.80; 95% CI 0.72–0.90; P < 0.001) 2,3 .”
InfluentialChen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Nanna, M. G., Doan, Q. V., Fabricatore, A., Faurby, M., Henry, A. D., Houshmand‐Oeregaard, A., Levine, A., Navar, A. M., Scassellati Sforzolini, T., & Toliver, J. C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16370 · Cited by 10
“12 See Table S7 for the probabilities of non-CV death.”
Evaluating the safety profile of semaglutide: an updated meta-analysis
Rivera, F. B., Arias-Aguirre, E., Aguirre, Z., Ybañez, M. J. C., Rubia, J. M. M., Galang, D. J. C., Lumbang, G. N. O., Ruyeras, J. M. M., Magalong, J. V., Pine, P. L. S., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2383731 · Cited by 14
McVay, M. A., Moore, W. S., Wilkins, F. L., Jackson, J. R., & Robinson, M. D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.783 · Cited by 10
Shirin, H., Neeland, I. J., Ryan, D. H., de Luis, D. A., Lecube, A., MAGOS, Z., Kenan, Y., Amir, R., Cohen, D. L., & Johansen, O. E. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100094 · Cited by 10
Self-citationSabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 17
“Nevertheless, the largest and longest randomized trial (194 participants, 96 weeks) of GLP-1RAs in PD evaluating once-weekly exenatide failed to show a benefit 138 .”
Harris, M., Harvie, M., & Renehan, A. G. (2025) · Cancers · doi:10.3390/cancers17091451 · Cited by 10
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Betensky, D. J., Smith, K. C., Katz, J. N., Yang, C. J., Hunter, D. J., Collins, J. E., Feldman, C. H., Messier, S. P., Kim, J., Selzer, F., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-03609 · Cited by 20
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
Neppala, S., Rajan, J., Yang, E., & DeFronzo, R. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02055-0 · Cited by 12
Park, B., Dennis, F., He, A. Z., Krishnaraj, A., Bakbak, E., Dennis, C. J., Pan, Y., Misner, E., Thayanithy, V., Lambotharan, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf690 · Cited by 17
Khalil, I., Islam, M. R., Kamrul-Hasan, A. B. M., Nagendra, L., Promi, S. A., Sayed, M. A., Rahman, M. A., Sultana, N., Tasmi, N. A., Das, M., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.005 · Cited by 13
Fang, Y. E., Paik, J. M., Ortega-Montiel, J., Tesfaye, H., Wexler, D. J., & Patorno, E. (2025) · Diabetes Care · doi:10.2337/dc25-1840 · Cited by 15
Timóteo, A. T., de Albuquerque, F. B., & Teixeira, B. L. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132303 · Cited by 16
Targeting obesity for therapeutic intervention in heart failure patients
Sato, R., & von Haehling, S. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2363395 · Cited by 10
Smith, G. D., & Ebrahim, S. B. J. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae179 · Cited by 12
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10
“However, the results of the SELECT trial highlight the importance of treating obesity to reduce cardiovascular risk (38).”
Quispe, R., Sweeney, T. E., Martin, S. S., Jones, S. R., Allison, M., Budoff, M. J., Ndumele, C. E., Elshazly, M. B., & Michos, E. D. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030548 · Cited by 11
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
Impacto de la obesidad y la diabetes en la salud y en la enfermedad cardiovascular
Lecube, A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103045 · Cited by 34
Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan
Inoue, K., Decker, S. R. D. R., Shi, I., Liang, L., Song, Y. S., Khan, S. S., & Kazi, D. S. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.3109 · Cited by 12
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
Mannucci, E., & Dicembrini, I. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01135-0 · Cited by 16
Legal, safety, and practical considerations of compounded injectable semaglutide
Spitery, A., Elder, M. J., Farhat, N., Mohammad, I., & Lobkovich, A. M. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1999 · Cited by 11
Sadraei, S., Aarabi, A., Firouzabadi, S. R., Alinejadfard, M., Mohammadi, I., & Jolfayi, A. G. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05278-3 · Cited by 14
Rivera, F. B., Bantayan, N. R. B., Aparece, J. P., Cruz, L. L. A., Magallong, J. V., Pine, P. L. S., Idian, A. M. N., Lumbang, G. N. O., Lerma, E. V., Lara-Breitinger, K. M., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.03.011 · Cited by 10
Perioperative Considerations for Patients on Semaglutide
Pai, S., Smith, M. A., Beam, W. B., & Harbell, M. W. (2024) · Current anesthesiology reports · doi:10.1007/s40140-024-00611-6 · Cited by 10
Novel oral agents in anti‐obesity pharmacotherapy: A narrative review
Buch, A., Eldor, R., Brown, R., & Zonszein, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16618 · Cited by 11
From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 16
The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review
Biondi, F., & Madonna, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082705 · Cited by 12
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US
Erhabor, J., Khorsandi, M., & Blaha, M. J. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.20105 · Cited by 9
Júnior, W. S. D. S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0015 · Cited by 13
NLRP3 inflammasomes pathway: a key target for Metformin
Hosseini, Y., Niknejad, A., Kashani, A. S., Gholami, M., Roustaei, M., Mohammadi, M. K., Momtaz, S., Atkin, S. L., Jamialahmadi, T., Abdolghaffari, A. H., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01702-4 · Cited by 13
Madsen, J. M., Kjaer, A. K., Lønborg, J. T., Køber, L., Glinge, C., Jabbari, R., & Engstrøm, T. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02548-w · Cited by 10
Mavraganis, G., Georgiopoulos, G. A., Athanasopoulos, S., Terentes-Printzios, D. G., Zervas, G., Konstantaki, C., Koilakou, M. E., Giannakopoulou, S., Dimopoulou, M., Chrysochoou, C., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70270 · Cited by 10
“Refining risk classification is particularly relevant with emerging obesity-targeting therapies, such as incretin-based treatments, 32 alongside redefining obesity to include CKM derangement, 33 to better identify high-risk individuals who would benefit most from intensified prevention.”
Nashwan, A. J., Abukhadijah, H. J., Vidusha, K., Aqtam, I. F., Ibraheem, A., Palanivelu, P., Khedr, M. A., Agga, A. O., Rehman, O. U., Fatima, E., et al. (2025) · Health Science Reports · doi:10.1002/hsr2.70638 · Cited by 12
James, S. K., Christoffersen, A., David, J., Hacker, M., Jensen, M. D. R. J., Mellbin, L., Pieber, T. R., Ripa, R. S., Rossing, P. R., Švehlíková, E., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.05.001 · Cited by 11
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
